Company Overview
| Stock Name | Abbisko-B |
|---|---|
| Stock Code | 02256 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們為一家臨床階段的生物製藥公司,致力於發現及開發創新且差異化的小分子腫瘤療法,已開發由14個專注於腫瘤學的候選藥物組成的管線,包括五種處於臨床階段的候選藥物。 |
| Listing Date | 2021-10-13 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市浦東新區張江高科技園區哈雷路898號3號樓 |
| Business Address (Hong Kong) | 香港灣仔皇后大道東248號大新金融中心40樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.abbisko.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 12.46 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 2,000 shares |
| Entry Threshold | HK$ 24,920 |
| Par Value | To be extracted |
| Offer Period | 2021-09-30 to 2021-10-06 |
| Global Offering Shares | 140,736,000 shares |
| HK Public Offer Shares (Initial) | 14,076,000 shares (10.0%) |
| Public Offer Lots (Initial) | 7,038lots (Pool A3,519lots,Pool B3,519lots) |
| International Placing Shares (Initial) | 126,660,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 702,466,350 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 56.6% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 1,753,570,560 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 2,000 | HK$ 24,920 |
| 2 lots | 4,000 | HK$ 49,840 |
| 3 lots | 6,000 | HK$ 74,760 |
| 4 lots | 8,000 | HK$ 99,680 |
| 5 lots | 10,000 | HK$ 124,600 |
| 6 lots | 12,000 | HK$ 149,520 |
| 7 lots | 14,000 | HK$ 174,440 |
| 8 lots | 16,000 | HK$ 199,360 |
| 9 lots | 18,000 | HK$ 224,280 |
| 10 lots | 20,000 | HK$ 249,200 |
| 15 lots | 30,000 | HK$ 373,800 |
| 20 lots | 40,000 | HK$ 498,400 |
| 25 lots | 50,000 | HK$ 623,000 |
| 30 lots | 60,000 | HK$ 747,600 |
| 35 lots | 70,000 | HK$ 872,200 |
| 40 lots | 80,000 | HK$ 996,800 |
| 45 lots | 90,000 | HK$ 1,121,400 |
| 50 lots | 100,000 | HK$ 1,246,000 |
| 60 lots | 120,000 | HK$ 1,495,200 |
| 70 lots | 140,000 | HK$ 1,744,400 |
| 80 lots | 160,000 | HK$ 1,993,600 |
| 100 lots | 200,000 | HK$ 2,492,000 |
| 110 lots | 220,000 | HK$ 2,741,200 |
| 120 lots | 240,000 | HK$ 2,990,400 |
| 130 lots | 260,000 | HK$ 3,239,600 |
| 140 lots | 280,000 | HK$ 3,488,800 |
| 150 lots | 300,000 | HK$ 3,738,000 |
| 175 lots | 350,000 | HK$ 4,361,000 |
| 200 lots | 400,000 | HK$ 4,984,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 225 lots | 450,000 | HK$ 5,607,000 |
| 250 lots | 500,000 | HK$ 6,230,000 |
| 350 lots | 700,000 | HK$ 8,722,000 |
| 400 lots | 800,000 | HK$ 9,968,000 |
| 500 lots | 1,000,000 | HK$ 12,460,000 |
| 1,000 lots | 2,000,000 | HK$ 24,920,000 |
| 3,519 lots | 7,038,000 | HK$ 87,693,480 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| HK Market Cap | HK$ 7.23B |
| Est. Threshold | HK$ 9.37B |
| Analysis Result | HK market cap below threshold, need +30% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 8,647,360,769 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不适用(公司处于亏损状态) |
| Profit/Loss Status | 2020年度亏损人民币706.6百万元 |
| Period-End Cash Balance | 人民币617.8百万元 |
| Listing Expenses | ~HK$ 147,360,160 |
| Listing Expenses / Funds Raised | ~8.4% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2019 | 2020 |
|---|---|---|
| Other income and gains, net | 12,705 | 18,831 |
| Administrative expenses | -21,891 | -21,168 |
| Operating profit | -133,389 | -706,301 |
| Net finance costs | -523 | -338 |
| Profit before tax | -133,912 | -706,639 |
| Income tax expense | 0 | 0 |
| Profit for the year | -133,912 | -706,639 |
Balance Sheet
| Item | 2019 | 2020 |
|---|---|---|
| Cash and cash equivalents | 285,637 | 617,773 |
| Total current assets | 300,181 | 649,802 |
| Total assets | 320,236 | 665,971 |
| Total current liabilities | 17,750 | 31,749 |
| Total liabilities | 779,261 | 1,770,959 |
| Total equity | -459,025 | -1,104,988 |
| Equity attributable to owners | -459,025 | -1,104,988 |
Cash Flow Statement
| Item | 2019 | 2020 | 2021-03 |
|---|---|---|---|
| Net cash from operating activities | -82,817 | -117,562 | |
| Net cash from investing activities | 30,127 | -11,246 | |
| Net cash from financing activities | 176,922 | 505,890 | |
| Net increase in cash | 124,232 | 377,082 | |
| Depreciation of PP&E | 3,108 | 3,482 | 1,210 |
| Depreciation of right-of-use assets | 5,086 | 5,871 | 1,468 |
| Amortisation of intangible assets | 0 | 138 | 100 |
| Purchase of PP&E | -3,435 | -3,462 | -765 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | Loading... |
|---|---|
| First Day Open | HK$ 11.30 |
| First Day Change | -13.56% |
| Use of Proceeds | 1、將撥付約19.7%或316.2百萬港元用于進行中的及未來的研發;
2、將撥付約32.6%或523.2百萬港元用于進行中的及未來的研發;
3、將撥付約28.0%或449.4百萬港元用于我們的其他臨床階段產品及我們管線的候選產品;
4、將撥付約8.4%或134.8百萬港元用于我們的臨床前研究,包括持續開發我們的研發平臺及研發新型臨床前候選藥物;
5、將撥付約6.3%或101.1百萬港元用于建造上海的生產設施;
6、約5.0%或80.3百萬港元將用作我們的營運資金及一般公司用途。 |
Underwriting Syndicate
Joint Sponsors (2)
Overall Coordinators (3)
Joint Bookrunners (7)
Joint Lead Managers (7)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | AIHC Master Fund | 46,550,560 HKD | — | 2.65% | — | 6 months | 2022-04-13 |
| 2 | Aranda Investments Pte. Ltd. | 77,575,960 HKD | — | 4.42% | — | 6 months | 2022-04-13 |
| 3 | BlackRock Funds | 77,575,960 HKD | — | 4.42% | — | 6 months | 2022-04-13 |
| 4 | Epsomite Gem Investments Ltd | 116,376,400 HKD | — | 6.64% | — | 6 months | 2022-04-13 |
| 5 | Hudson Bay Master Fund LTD | 77,575,960 HKD | — | 4.42% | — | 6 months | 2022-04-13 |
| 6 | Janchor Partners Pan-Asian Master Fund | 54,300,680 HKD | — | 3.10% | — | 6 months | 2022-04-13 |
| 7 | Lake Bleu Prime Healthcare Master Fund Limited | 77,575,960 HKD | — | 4.42% | — | 6 months | 2022-04-13 |
| 8 | LAV Star Limited | 155,176,840 HKD | — | 8.85% | — | 6 months | 2022-04-13 |
| 9 | OrbiMed Funds | 77,575,960 HKD | — | 4.42% | — | 6 months | 2022-04-13 |
| 10 | UBS Asset Management (Singapore) Ltd. | 155,176,840 HKD | — | 8.85% | — | 6 months | 2022-04-13 |
| 11 | Vivo Funds | 77,575,960 HKD | — | 4.42% | — | 6 months | 2022-04-13 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 徐耀昌 | — |
| Company Secretary | 田慧敏、陳燕華 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 徐耀昌、喻紅平、陳椎(一致行動人士)合共持有164,581,300股股份,佔緊隨全球發售完成後約23.43%(假設超額配股權未獲行使);施毅透過LAV實體持有約10.72%。 |
|---|




